Advertisement

Topics

R-Pharm out-licenses molecule for design of anti-cancer drugs to Aspyrian

11:03 EDT 29 Jul 2017 | thePharmaLetter

R-Pharm, one of Russia’s leading drugmakers, has signed an agreement with the USA’s clinical stage…

Original Article: R-Pharm out-licenses molecule for design of anti-cancer drugs to Aspyrian

NEXT ARTICLE

More From BioPortfolio on "R-Pharm out-licenses molecule for design of anti-cancer drugs to Aspyrian"

Quick Search
Advertisement
 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...